End of year scTrends update!
Long-form review, key news stories, and company & platforms deep dive
What a year it’s been! I thought I’d time this blogpost with the Cell Genomics release of our long form technology review covering where we are now and most exciting future directions.
News:
9JUL24 - Did Illumina’s acquisition of Fluent BioSciences trigger a rally?
Here was some news that didn’t quite make our Nature Biotech market report. To cut to the chase, this news was big — but probably not enough to explain trend below accounting for ~$5Bn of market cap. At this point, Illumina’s stock price will primarily be driven by core financials — however within a few days of the acquisition, we do a jump of ~$2Bn — for an acquisition in the range of ~$100m, that’s quite a return.
SEP/OCT24 - More Litigation!
10x Genomics continues to be involved in legal disputes with several companies in both the single-cell and spatial ‘omics field. Since submitting our review, Parse Biosciences was successful in invalidating one of the 10X patents in a US court although the overall dispute between the parties continues, and NanoString Technologies (now Bruker) was also successful in another dispute around spatial technologies in Europe. In both cases, challenges were made around novelty with respect to prior art, with 10x Genomics challenging the decisions from the courts.
Other news:
Singular Genomics M&A activity (not technically single cell/spatial ‘omics).
MGI/BGI is now a military arms supplier… or so says the US government!
Making this a living review!
You may have heard us reference scTrends as a “living review”. We’ve wanted to make sure our resources are up to date for anyone to access, so here goes:
Our company-by-company review of every platform on the market (originally planned as the appendix to our Cell Genomics piece)
Side-by-side comparison of technical specifications (static versions of these are included as part of the Cell Genomics supplement)